Targeting a specific cell death process in aggressive lung cancer types
Official title: Targeting ferroptosis in aggressive subtypes of lung cancer
Funded at Icahn School of Medicine at Mount Sinai · NIH-11133425 · Data updated 2026-11-12
This study is looking at ways to help people with a specific type of lung cancer that has certain gene mutations, by finding new treatments that can make the cancer cells die off more effectively, which could improve their overall care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $689,914 |
| NIH project number | 1R01CA293642-01A1 |
| Project ID | NIH-11133425 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with STK11/KEAP1 co-mutant non-small cell lung cancer.
✕Less likely to help
Patients with other types of lung cancer or those without the STK11/KEAP1 mutations may not benefit from this research.
What this research studies
This research focuses on improving treatment outcomes for patients with a specific type of non-small cell lung cancer (NSCLC) that has mutations in the STK11 and KEAP1 genes. The study investigates how these mutations allow cancer cells to evade a form of cell death known as ferroptosis, which is crucial for controlling tumor growth. By using advanced techniques like CRISPR/Cas9, the researchers aim to identify new therapeutic strategies that can induce ferroptosis in these resistant cancer cells, potentially enhancing the effectiveness of existing treatments. The goal is to better understand the mechanisms behind this resistance and develop targeted therapies that can overcome it.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival rates for patients with aggressive lung cancer.
How similar studies have gone: While targeting ferroptosis is a relatively novel approach, preliminary studies have shown promise in similar cancer types, indicating potential for success.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Sen, Triparna — Icahn School of Medicine at Mount Sinai
- Study coordinator: Sen, Triparna
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.